Bookmark and Share

$VTGN Announces Preclinical Data Demonstrating Differentiated Mechanism of Action of PH10 from Benzodiazepines

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced promising preclinical data for its PH10 drug candidate. The data demonstrate that the potential mechanism of action of PH10, VistaGen’s Phase 2 investigational pherine nasal spray with potential as a rapid-onset, stand-alone treatment for major depressive disorder (“MDD”), does not involve direct activation of GABA-A receptors. This is in distinct contrast to the mechanism of action of benzodiazepines, which act as direct positive modulators of GABA-A receptors. Instead, PH10 is designed to engage receptors in nasal chemosensory neurons, which in turn regulate limbic amygdala neurons that release excitatory neurotransmitters producing rapid-onset antidepressant effects. “These preclinical data suggest that PH10’s mechanism of action does not work through GABA-A receptors, unlike many other neurosteroids, suggesting it may not have benzodiazepine-like side effects, such as sedation and cognitive impairment, or abuse liability,” said VistaGen’s Chief Medical Officer Mark Smith, MD, PhD. “Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors. While PH10 may regulate endogenous GABA circuits in the brain, it does not appear to directly bind to or modulate GABA receptors at concentrations of less than 10 micromolar, which differentiates its mechanism of action from that of benzodiazepines.”

To view the full press release, visit http://ibn.fm/a4enX

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on TwitterLinkedIn and Facebook.

*Monti, L., & Liebowitz, M. (2020). Neural circuits of anxiolytic and antidepressant pherine molecules. CNS Spectrums, 1-7. doi:10.1017/S109285292000190X

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, March 11th, 2021 Uncategorized